分子靶向治疗改善非小细胞肺癌的放射治疗效果。
Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.
机构信息
1 Department of Internal medicine, University of Missouri, Kansas City, MO, USA ; 2 Department of Radiation Oncology, Government Medical College, Haldwani, Nanital, India ; 3 Department of Pulmonary Medicine and Critical Care, University of Oklahoma, Norman, OK, USA ; 4 Department of Internal Medicine, University of Missouri, Kansas City, MO, USA ; 5 Department of Hematology and Oncology, Saint Luke's Hospital, Kansas City, MO, USA.
出版信息
Ann Transl Med. 2016 Feb;4(3):50. doi: 10.3978/j.issn.2305-5839.2015.10.35.
Effective treatments for non-small cell lung carcinoma (NSCLC) remain elusive. The use of concurrent chemotherapy with radiotherapy (RT) has improved outcomes, but a significant proportion of NSCLC patients are too frail to be able to tolerate an intense course of concurrent chemoradiotherapy. The development of targeted therapies ignited new hope in enhancing radiotherapeutic outcomes. The use of targeted therapies against the epidermal growth factor receptor (EGFR) has offered slight but significant benefits in concurrent use with RT for certain patients in certain situations. However, despite theoretical promise, the use of anti-angiogenics, such as bevacizumab and endostatin, has not proven clinically safe or useful in combination with RT. However, many new targeted agents against new targets are being experimented for combined use with RT. It is hoped that these agents may provide a significant breakthrough in the radiotherapeutic management of NSCLC. The current review provides a brief discussion about the targets, the targeted therapies, the rationale for the use of targeted therapies in combination with RT, and a brief review of the existing data on the subject.
有效的非小细胞肺癌（NSCLC）治疗方法仍然难以捉摸。放化疗（RT）的联合应用改善了治疗效果，但相当一部分 NSCLC 患者身体过于虚弱，无法耐受强化的同期放化疗。靶向治疗的发展为提高放射治疗效果带来了新的希望。针对表皮生长因子受体（EGFR）的靶向治疗在某些情况下与 RT 联合使用时，为某些患者带来了微小但显著的益处。然而，尽管有理论上的前景，但抗血管生成药物，如贝伐单抗和内皮抑素，与 RT 联合使用在临床上并未被证明是安全或有效的。然而，许多针对新靶点的新型靶向药物正在与 RT 联合应用进行试验。人们希望这些药物可能为 NSCLC 的放射治疗管理带来重大突破。本文简要讨论了相关靶点、靶向治疗、将靶向治疗与 RT 联合应用的原理，并对该主题的现有数据进行了简要回顾。
Zotero 插件